We are updating our Privacy Policy and Terms and Conditions to help you clearly understand how your personal information is collected, stored and managed. Learn More
Menu Back toOversight-in-the-Era-of-E6-R2

DIA 2018 Global Annual Meeting

The DIA 2018 Global Annual Meeting brings together thousands of innovators from around the globe.

Oversight in the Era of E6 (R2)

    Session Chair(s)
      Melissa  Bomben, MS

      Melissa Bomben, MS

      • Vice President, Strategic Resourcing
      • Syneos Health, United States
    This session will outline the characteristics that define common outsourcing models and expose their corresponding risk/benefit ratio with regard to sponsor and CRO oversight. Case studies of proven solutions within each model will be presented and linked to recommendations to achieve enhanced oversight in the era of E6 (R2).
    Learning Objective : Discuss the risk/benefit ratio with regard to sponsor and CRO oversight in common outsourcing models; Identify methods to implement improved and more efficient approaches to clinical trial oversight.
      Cristin  MacDonald, PhD

      Outsourcing Models

      Cristin MacDonald, PhD

      • Executive Director, Client Delivery
      • The Avoca Group, United States
      Lauren  Curtiss


      Lauren Curtiss

      • GCP Inspection Lead
      • Merck & Co., Inc., United States